Strategic focus Target mitochondrial disease programs and cardiovascular/ophthalmic disease areas with small molecule therapeutics, aligning BD efforts around OMEICOS’s lead program OMT-28 and its Phase 2a study for Primary Mitochondrial Disease to identify co-development or licensing opportunities.

Funding momentum Leverage recent grant funding and ongoing investor interest to position partnerships or milestone-based collaborations, offering risk-sharing deals and co-development financing to accelerate clinical milestones for OMT-28 and related compounds.

Clinical readiness Emphasize the oral small molecule advantage and improved PK/PD properties to engage CROs, contract manufacturers, and clinical trial networks for Phase 2a execution, while identifying potential for broader orphan/rare disease indications with mitochondrial involvement.

Market signaling Capitalize on public financing activity and past Series B/C momentum to approach strategic pharma players with interest in cardiovascular and ophthalmic therapies, proposing collaboration on later-stage development, manufacturing scale-up, or regional commercialization rights.

Team and governance Highlight experienced leadership and board composition from Forbion connections to build credibility in BD outreach, proposing co-investment and advisory-led partnerships that leverage their network to accelerate business development conversations.